When it comes to cancer, time is of the essence for patients and their families. With TumorSight IQ, breast surgeons and their patients can discuss surgical options earlier to aid in the evaluations of services needed at the time of definitive surgery by visualizing tumor response to neoadjuvant therapy.
*This device is not FDA cleared or approved
Generates a 3D representation of the patient's post-treatment tumor and surrounding tissue.
Post neoadjuvant treatment, visualize the change in tumor volume.
Provides size, extent, and location of residual disease and its relationship to landmark structures.
TumorSight IQ uses mathematical models derived from computational spatial biophysics to estimate response. It has been shown that TumorSight IQ determined the tumor volume at baseline, during, and after physician chosen therapy with only 6.7% error. To learn more, read our published study here.
With only standard-of-care diagnostic data and our spatial biophysics unlocked with AI and data science, TumorSight IQ creates digital twin of a patient's tumor that recapitulates its unique tumor biology and behavior upon treatment.
Dynamic Contract-Enhanced MRI
HER2, HR, Histology, Staging, Grade
Age, Race
Neoadjuvant Chemotherapy
©SimBioSys
